FAKTOR-OPTIONSSCHEIN - HALEON Stock

Certificat

DE000MD7LDG3

Real-time Bid/Ask 07:21:56 2024-05-23 am EDT
9.86 EUR / 9.91 EUR +5.72% Intraday chart for FAKTOR-OPTIONSSCHEIN - HALEON
Current month-6.97%
1 month-8.87%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 9.86 +5.45%
24-05-22 9.35 -3.71%
24-05-21 9.71 -3.86%
24-05-20 10.1 +6.09%
24-05-17 9.52 -1.24%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 06:49 am EDT

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying HALEON PLC
Issuer Morgan Stanley
WKN MD7LDG
ISINDE000MD7LDG3
Date issued 2022-08-30
Strike 265.3 p
Maturity Unlimited
Parity 0.08 : 1
Emission price 10
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 24.55
Lowest since issue 5.91
Spread 0.05
Spread %0.50%

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
-
More about the company

Ratings for Haleon plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Haleon plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.311 GBP
Average target price
3.62 GBP
Spread / Average Target
+9.33%
Consensus